Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041)

Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00211601

Acronym

C-PHONE

Enrollment

1500

Registered

2005-09-21

Start date

2004-08-31

Completion date

2005-12-31

Last updated

2015-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy Induced Nausea and Vomiting

Brief summary

The purpose of this study is to assess whether timely feedback to providers on patient experiences with delayed chemotherapy induced nausea and vomiting (CINV) lead to differences in patient outcomes for subsequent cycles.

Interventions

BEHAVIORALDisease Management Assessment

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Highly or moderately emetogenic chemotherapy planned for at least 2 cycles

Exclusion criteria

* Concurrent other anti-cancer therapy (e.g. radiation, hormone, etc.); vomiting during the 24 hours prior to first chemotherapy cycle; having a disease/condition or taking medication that may cause emesis

Design outcomes

Primary

Measure	Time frame
CINV at the delayed phase during cycle 2	—

Secondary

Measure	Time frame
Treatment for CINV	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026